ERBB2 and non-small cell lung carcinoma: Clinical trials exploring these novel combinations are ongoing in HER2-mutant NSCLC, with encouraging results from studies like the DESTINY-Lung trials, zongertinib Beamion LUNG-1 studies, and other phase I/II studies testing the synergy between HER2-targeted therapies and ICIs.